J&J inks $1.25B deal to buy rights to atopic dermatitis candidate from Numab
J&J inks $1.25B deal to buy rights to atopic dermatitis candidate from Numab
J&J inks $1.25B deal to buy rights to atopic dermatitis candidate from Numab
Published: May 28, 2024
By Tyler Patchen
BioSpace
Johnson & Johnson is continuing its buying activity in the skin disease space, announcing Tuesday plans to purchase Yellow Jersey Therapeutics, a subsidiary of Numab Therapeutics, and its bispecific antibody NM26 for $1.25 billion in cash.
NM26, which started Phase I dosing in 2023, is ready to enter Phase II studies and targets two pathways to treat the skin disease atopic dermatitis (AD) or eczema. The pathways are the IL-4R alpha subunit (IL-4Rα) and IL-31. Il-4Rα triggers Th2-mediated skin inflammation, while Il-31 impacts skin itching and eventual scratching that worsen the condition.
“We are committed to developing differentiated bispecifics that combine the targeting of two distinct disease-driving pathways. NM26 can potentially deliver a treatment specifically for patients with inflamed skin associated with intense itching,” David Lee, the global immunology therapeutic area head at J&J Innovative Medicine, said in a statement.
J&J contends the candidate could effectively treat other inflammatory skin diseases that involve Th2 inflammation and itching. The deal is expected to close in the second half of 2024.
Earlier this month, J&J announced it purchased biotech Proteologix and its bispecific antibody for AD for $850 million in a cash deal and a preclinical antibody. The candidate PX128 targets interleukin 13 TSLP and is in a Phase I trial for AD. The preclinical asset that J&J also scooped up in the deal, PX130, targets Il-13 and Il-22 for moderate to severe AD.
“Our goal is to deliver transformational efficacy for all patients living with immune mediated diseases like AD,” Candice Long, worldwide vice president of immunology at J&J, said in a statement. “Our investment in differentiated bispecifics is the next chapter in our impactful Immunology legacy. It reinforces our commitment to address unmet medical needs by leveraging patient insights and our deep disease expertise.”
Numab has forged partnerships with other pharmaceutical companies, such as a development and licensing agreement with Ono Pharmaceutical in March 2024 to find an immuno-oncology candidate. The Swiss biotech received CHF 258 million ($283 million) in upfront research and milestone payments in that deal. Numab has also entered into previous development agreements with Eisai and Boehringer Ingelheim.
Tyler Patchen is a staff writer at BioSpace. You can reach him at [email protected]. Follow him on LinkedIn.
Source: BioSpace
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds: